Drugs /

budigalimab

Back to Drugs List

Overview

NCI Definition [1]:
A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody ABBV-181 targets and binds to PD-1, thereby blocking its binding to the PD-1 ligand, programmed cell death-1 ligand 1 (PD-L1), and preventing the activation of PD-1/PD-L1 downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs). PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.

Clinical Trials

View Clinical Trials for budigalimab

Budigalimab has been investigated in 12 clinical trials, of which 11 are open and 1 is closed. Of the trials investigating budigalimab, 11 are phase 1 (10 open) and 1 is phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for budigalimab clinical trials.

Malignant solid tumor, head and neck squamous cell carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in budigalimab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Budigalimab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Budigalimab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating budigalimab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
budigalimab, abbv 181, abbv181, abbv-181
Drug Target(s) [2]:
PDCD1
NCIT ID [1]:
C137682

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.